".....we were delighted to report positive preclinical data on the ability of PAT-DX3 to be used for synthetic lethality strategies which, along with its potential for the delivery of therapeutic payloads into the cell and cell nucleus, remains an area of high interest with potential partners.”
- Forums
- ASX - By Stock
- PAB
- Ann: Appendix 4C - Quarterly - 31 March 2023
Ann: Appendix 4C - Quarterly - 31 March 2023, page-2
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M |
Open | High | Low | Value | Volume |
0.6¢ | 0.6¢ | 0.6¢ | $429 | 71.43K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 2134480 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1128726 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 2134480 | 0.006 |
15 | 7449991 | 0.005 |
11 | 6764199 | 0.004 |
6 | 6065682 | 0.003 |
2 | 2770000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1128726 | 3 |
0.008 | 1661233 | 4 |
0.009 | 431000 | 1 |
0.010 | 396000 | 5 |
0.011 | 680000 | 2 |
Last trade - 12.08pm 03/09/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |